▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #824 by analyst upside · 2026-11-12
CMPS
COMPASS Pathways plc
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+150.7%
implied upside to consensus target
Current Price $9.3
Consensus Target $23.31
Bull Target $65.0
Bear Target $10.0
Analysts Covering 16
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
12
Hold
1
Sell
0
52-Week Low $4.88
52-Week High $15.87
YTD Return +42.0%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.36
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.88
52-Week High $15.87
Current Price $9.3
Bear Target $10.0
Bull Target $65.0
● Now $9.3 ● Target $23.31
TRADING DATA
Avg Volume 3.0M
YTD Return +42.0%
Analyst Count 16
Consensus Buy
Upside to Target +150.7%
Last Updated 2026-11-12

ANALYST SUMMARY

COMPASS Pathways plc (CMPS) is currently trading at $9.3 with a Wall Street consensus price target of $23.31, implying potential upside of 150.7% over the next 12 months. 16 analysts currently cover CMPS, with a consensus rating of Buy - 94% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $65.0, while the most cautious has a target of $10.0.

CMPS operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 42.0% year-to-date and is currently trading near the lower end of its 52-week range of $4.88 – $15.87.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GTBIF +143.2%
Green Thumb Industries Inc.
$1B · P/E 15.7x · Buy
VOR +94.1%
Vor Biopharma Inc.
$1B · P/E 0.1x · Buy
DMRA +101.2%
Damora Therapeutics, Inc.
$1B · P/E 14.1x · Buy
INVA +84.5%
Innoviva, Inc.
$1B · P/E 8.1x · Buy
NRIX +105.1%
Nurix Therapeutics, Inc.
$2B · P/E 6.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CMPS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-11-04 Building track record
BTIG reit
Buy → Buy 2026-11-03 38% win rate (8 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-08-07 31% win rate (48 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-08-06 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-08-06 Building track record
B. Riley Securities - Reiterated
Buy → Buy 2026-08-06 17% win rate (6 calls)
Wells Fargo ● Initiated
Equal-Weight 2026-07-27 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-07-08 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
22/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →